Reading a Longevity Claim: What the Human Evidence on NAD+ Actually Shows

"NAD+" and "longevity" show up together in a lot of telehealth ads right now, usually next to words like "reverse aging" or "restore your youth." Before deciding whether any of that applies to you, it helps to know what the actual human research has measured, and what it hasn't.

What NAD+ is, briefly

NAD+ is a coenzyme every cell uses in energy metabolism and in the cellular repair processes that run in the background all day. Some research reports that levels measured in blood tend to decline with age, which is part of why NAD+ became a target for research and, separately, for marketing. Cell studies and animal studies have looked at a wide range of effects. Human trials are a much smaller, more specific body of evidence, and that's the part worth reading carefully before any purchase decision.

Most human trials tested a pill, not an injection or spray

If you search for the actual clinical trials behind NAD+ marketing, a pattern shows up quickly: the studies with real data mostly gave people an oral capsule, usually nicotinamide riboside, sometimes combined with pterostilbene. That's a different delivery method from the injections, drops, and nasal sprays sold under "NAD+ therapy" branding.

Two of the better-known trials illustrate this. Airhart and colleagues gave 140 healthy, overweight adults ages 40 to 60 either a placebo or one of three doses of oral nicotinamide riboside (100, 300, or 1000 mg per day) for eight weeks. Dellinger and colleagues gave 120 healthy adults ages 60 to 80 either a placebo or oral nicotinamide riboside combined with pterostilbene, also for eight weeks. Both were randomized, double-blind, and placebo-controlled, which is a solid design for the question they were actually asking.

That question was: does this raise measured NAD+ in blood, and is it safe to take? It was not: does this reverse aging, extend lifespan, or prevent disease.

What "raised NAD+ levels" actually means

In the Airhart trial, blood NAD+ rose in a dose-dependent way, from about 22 percent at the lowest dose to 142 percent at the highest, and stayed elevated through the eight weeks. In the Dellinger trial, NAD+ rose about 40 percent at the lower combined dose and about 90 percent at the higher dose by week four, with the placebo group showing no change. Both trials reported that the compound was generally well tolerated, with no serious adverse events and no meaningful difference in side effects between the treatment and placebo groups.

That's a real, measured result: a blood marker went up, and short-term safety looked acceptable in these specific groups. It is not the same claim as "you will feel younger," "your cells will repair faster," or "this adds years to your life." No human trial has shown that raising blood NAD+ extends lifespan or reverses the aging process. Individual results vary, and a lab value moving in a narrow, screened group of trial participants doesn't tell you what will happen for any one person.

Who these trials actually studied

A third trial, published in GeroScience, looked at a narrower group: 20 older adults with mild cognitive impairment, given an escalating dose of oral nicotinamide riboside up to 1 gram per day over 10 weeks. It, too, found the compound well tolerated with no serious adverse events, and it significantly raised blood NAD+. But a pilot study of 20 people with a specific diagnosis doesn't establish a benefit for the general population, and the researchers didn't design or report it as one.

Across the three trials, the populations were healthy overweight adults, healthy older adults, and older adults with mild cognitive impairment. None enrolled a broad "anyone interested in longevity" group, and none measured disease prevention or lifespan.

Why the gap between "measured" and "marketed" matters

This distinction matters because a lot of the marketing language around NAD+ programs implies a much bigger claim than the evidence supports. The FTC's health products guidance sets the bar an advertiser has to clear: every objective health claim needs competent and reliable scientific evidence behind it, disease treatment claims need robust support and can be implied by a product name or an image as easily as by a sentence, and results shown to a reader have to be what a typical buyer can expect rather than a best case with a disclaimer attached. If a page tells you it will restore your youth or extend your life, that claim is not coming from the trials cited above, because those trials didn't test for it.

None of this means the underlying research is meaningless. A dose-dependent rise in a measurable blood marker, replicated across separate trials with a reasonable short-term safety profile, is a legitimate finding. It's just a narrower finding than "anti-aging," and it's worth holding those two things apart when you're deciding what a claim is actually telling you.

If you want a closer look at how these claims line up against the underlying trials, Health Stacker's peptide guide collection walks through how to read this kind of evidence across several common longevity claims.

Any NAD+ program that involves compounded medication, whether injection, drops, or nasal spray, should be discussed with a licensed provider first. Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Providers, not marketing copy, are the ones positioned to say whether a program makes sense for your history. One option in this space is the Luvo Health longevity program page, which uses licensed U.S. providers for its NAD+ and sermorelin programs.

Sources

• Federal Trade Commission, "Health Products Compliance Guidance": https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance. Not a clinical study; the FTC's standard for health advertising, requiring competent and reliable scientific evidence for objective claims, robust support for disease claims including ones implied by names or images, and results that reflect what a typical buyer can expect; sets an advertising standard, not evidence about NAD+ itself.
• Airhart et al., "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride)," PLOS ONE, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/. 140 healthy overweight adults, ages 40-60; oral nicotinamide riboside, 100/300/1000 mg/day; 8 weeks, randomized, double-blind, placebo-controlled; endpoint: dose-dependent NAD+ increase of 22-142 percent, no significant difference in adverse events vs. placebo; limitation: measured blood NAD+ and short-term safety only, not aging or disease outcomes.
• Dellinger et al., "Repeat dose NRPT increases NAD+ levels in humans safely and sustainably," npj Aging and Mechanisms of Disease, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5701244/. 120 healthy adults ages 60-80; oral nicotinamide riboside plus pterostilbene vs. placebo; 8 weeks, randomized, double-blind, placebo-controlled; endpoint: safety, tolerability, and NAD+ elevation in an older population; limitation: safety-focused design, not a longevity or disease-outcome study.
• "A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment," GeroScience, 2023. https://pubmed.ncbi.nlm.nih.gov/37994989/. 20 older adults with mild cognitive impairment; oral nicotinamide riboside, dose-escalated to 1 g/day; 10 weeks, randomized, placebo-controlled pilot study; endpoint: cognition and NAD+-related measures in a specific clinical population; limitation: small pilot sample in a narrow clinical population, not generalizable to broader "anti-aging" claims.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.